{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T03:36:43Z","timestamp":1772768203490,"version":"3.50.1"},"reference-count":24,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2019,8,15]],"date-time":"2019-08-15T00:00:00Z","timestamp":1565827200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec><jats:title>Study Objective<\/jats:title><jats:p>Buprenorphine, a partial \u03bc\u2010opioid agonist, is an effective treatment for opioid use disorder that conventionally requires symptoms of withdrawal before initiation to avoid precipitating withdrawal. Our institution implemented a microdosing approach to transition patients from full \u03bc\u2010opioid agonists to buprenorphine without requiring patients to undergo a period of opioid abstinence. Little has been published about this strategy in the inpatient setting in the United States, and even less has been published dealing with the transition from methadone to buprenorphine. Our objective was to demonstrate that a microdosing protocol to transition patients from methadone to buprenorphine can be feasibly implemented in a U.S. hospital setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>Case series.<\/jats:p><\/jats:sec><jats:sec><jats:title>Patients<\/jats:title><jats:p>Three hospitalized adults with opioid use disorder who received a 1\u2010week buprenorphine microdosing protocol.<\/jats:p><\/jats:sec><jats:sec><jats:title>Measurements and Main Results<\/jats:title><jats:p>In January 2019, we implemented a 1\u2010week buprenorphine microdosing protocol for hospitalized adult patients with opioid use disorder who were initially stabilized on methadone and wished to start buprenorphine. We gave low\u2010dose buprenorphine concurrently with each patient's full dose of methadone, and the buprenorphine dose was gradually titrated up over 7\u00a0days. On day 8, methadone was abruptly discontinued. The buprenorphine dose was further increased based on clinical judgment. All three patients were successfully transitioned from methadone 40\u2013100\u00a0mg\/day to buprenorphine 12\u201316\u00a0mg\/day with minimal symptoms of opioid withdrawal. One patient relapsed and was lost to follow\u2010up; two remained in treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>A protocol using microdosing of buprenorphine can successfully transition patients receiving full \u03bc\u2010opioid agonist therapy, including methadone, to buprenorphine without the need for a period of opioid abstinence.<\/jats:p><\/jats:sec>","DOI":"10.1002\/phar.2313","type":"journal-article","created":{"date-parts":[[2019,7,26]],"date-time":"2019-07-26T09:22:48Z","timestamp":1564132968000},"page":"1023-1029","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Transitioning Hospitalized Patients with Opioid Use Disorder from Methadone to Buprenorphine without a Period of Opioid Abstinence Using a Microdosing Protocol"],"prefix":"10.1002","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8164-1608","authenticated-orcid":false,"given":"Dale","family":"Terasaki","sequence":"first","affiliation":[{"name":"Addition Medicine Fellowship University of Colorado Hospital, CeDAR Aurora Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Medicine Hospital Medicine University of Colorado Hospital Aurora Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan L.","family":"Calcaterra","sequence":"additional","affiliation":[{"name":"Department of Medicine Hospital Medicine University of Colorado Hospital Aurora Colorado"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2019,8,15]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/M17-3107"},{"issue":"2","key":"e_1_2_6_3_1","first-page":"CD002207","article-title":"Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence","author":"Mattick RP","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_6_4_1","unstructured":"SAMHSA.Buprenorphine [Internet].2016. Available fromhttps:\/\/www.samhsa.gov\/medication-assisted-treatment\/treatment\/buprenorphine."},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1151\/spp04224"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1994.71"},{"key":"e_1_2_6_7_1","unstructured":"CasadonteP SullivanM.Buprenorphine Induction [Internet]. Providers\u2019 Clinical Support System (PCSS);2013. Available fromhttps:\/\/pcssnow.org\/wp-content\/uploads\/2014\/02\/PCSS-MATGuidanceBuprenorphineInduction.Casadonte.pdf. Accessed May 7 2019."},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1080\/00952990802342899"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.2147\/SAR.S109919"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2015.01.004"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2016.16050548"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.02.002"},{"key":"e_1_2_6_13_1","doi-asserted-by":"crossref","unstructured":"KlaireS ZivanovicR BarbicSP SandhuR MathewN AzarP.Rapid micro\u2010induction of buprenorphine\/naloxone for opioid use disorder in an inpatient setting: a case series. American Journal on Addictions [Internet]. Available fromhttp:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/ajad.12869. Accessed March 29 2019.","DOI":"10.1111\/ajad.12869"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/ajad.12809"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/02791072.2019.1610200"},{"key":"e_1_2_6_16_1","unstructured":"ZamanT.Webinar: Transdermal buprenorphine for induction of patients with co\u2010morbid pain. Powerpoint presentation presented at CSAM Webinar; March 13 2019."},{"issue":"1","key":"e_1_2_6_17_1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/02024458-201706000-00006","article-title":"Case report: high\u2010dose methadone transition to buprenorphine\/naloxone in an inpatient with a prolonged QT interval","volume":"8","author":"Cortina S","year":"2017","journal-title":"Can J Addict"},{"key":"e_1_2_6_18_1","unstructured":"McLeanM.OAT transitions\u2014focus on microdosing [Internet]. Powerpoint presentation presented at BOOST Collaborative Learning Session 3; June 14 2018; Vancouver BC. Available fromhttp:\/\/stophivaids.ca\/STOP\/wp-content\/uploads\/Microdosing-McLean-BOOST-14-June-2018.pdf."},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310480"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0030-1261914"},{"key":"e_1_2_6_21_1","unstructured":"CasadonteP SullivanM.Transfer from methadone to buprenorphine [Internet]. Providers\u2019 Clinical Support System (PCSS);2013. Available fromhttps:\/\/pcssnow.org\/wp-content\/uploads\/2014\/03\/PCSS-MATGuidanceTransferMethadonetoBup.Casadonte.pdf. Accessed May 17 2019."},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.4065\/80.8.991"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1808312"},{"key":"e_1_2_6_24_1","unstructured":"HedegaardH WarnerM Mini\u00f1oAM.Drug Overdose Deaths in the United States 1999\u20132016 | NCHS Data Brief 294 [Internet]. December 2017 p. 4. Available fromhttps:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db294_table.pdf."},{"key":"e_1_2_6_25_1","unstructured":"VogelM.Overlapping Transition from Morphine sulfate\/Methadone\/L\u2010Polamidone to Buprenorphine. Psychiatric University Clinics;2019."}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.2313","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2313","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/phar.2313","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.2313","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T09:47:32Z","timestamp":1761040052000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.2313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,15]]},"references-count":24,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["10.1002\/phar.2313"],"URL":"https:\/\/doi.org\/10.1002\/phar.2313","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"value":"0277-0008","type":"print"},{"value":"1875-9114","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,15]]},"assertion":[{"value":"2019-08-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}